Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma.

Benavides-Serrato A, Saunders JT, Holmes B, Nishimura RN, Lichtenstein A, Gera J.

Int J Mol Sci. 2020 Jan 5;21(1). pii: E344. doi: 10.3390/ijms21010344.

2.

The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.

Holmes B, Benavides-Serrato A, Saunders JT, Landon KA, Schreck AJ, Nishimura RN, Gera J.

J Neurooncol. 2019 Oct;145(1):11-22. doi: 10.1007/s11060-019-03274-0. Epub 2019 Aug 31.

PMID:
31473880
3.

A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity.

Vega MI, Shi Y, Frost P, Huerta-Yepez S, Antonio-Andres G, Hernandez-Pando R, Lee J, Jung ME, Gera JF, Lichtenstein A.

Mol Cancer Ther. 2019 Oct;18(10):1822-1831. doi: 10.1158/1535-7163.MCT-19-0115. Epub 2019 Aug 8.

PMID:
31395691
4.

Discovering the chloride pathway in the CFTR channel.

Farkas B, Tordai H, Padányi R, Tordai A, Gera J, Paragi G, Hegedűs T.

Cell Mol Life Sci. 2019 Jul 20. doi: 10.1007/s00018-019-03211-4. [Epub ahead of print]

PMID:
31327045
5.

Effects of the Pentapeptide P33 on Memory and Synaptic Plasticity in APP/PS1 Transgenic Mice: A Novel Mechanism Presenting the Protein Fe65 as a Target.

Szögi T, Schuster I, Borbély E, Gyebrovszki A, Bozsó Z, Gera J, Rajkó R, Sántha M, Penke B, Fülöp L.

Int J Mol Sci. 2019 Jun 22;20(12). pii: E3050. doi: 10.3390/ijms20123050.

6.

Correction: Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma.

Benavides-Serrato A, Lee J, Holmes B, Landon KA, Bashir T, Jung ME, Lichtenstein A, Gera J.

PLoS One. 2019 Feb 6;14(2):e0212160. doi: 10.1371/journal.pone.0212160. eCollection 2019.

7.

Key Peptides and Proteins in Alzheimer's Disease.

Penke B, Bogár F, Paragi G, Gera J, Fülöp L.

Curr Protein Pept Sci. 2019;20(6):577-599. doi: 10.2174/1389203720666190103123434. Review.

PMID:
30605056
8.

The Role of Lipids and Membranes in the Pathogenesis of Alzheimer's Disease: A Comprehensive View.

Penke B, Paragi G, Gera J, Berkecz R, Kovács Z, Crul T, VÍgh L.

Curr Alzheimer Res. 2018;15(13):1191-1212. doi: 10.2174/1567205015666180911151716. Review.

PMID:
30207230
9.

Searching for improved mimetic peptides inhibitors preventing conformational transition of amyloid-β42 monomer.

Gera J, Szögi T, Bozsó Z, Fülöp L, Barrera EE, Rodriguez AM, Méndez L, Delpiccolo CML, Mata EG, Cioffi F, Broersen K, Paragi G, Enriz RD.

Bioorg Chem. 2018 Dec;81:211-221. doi: 10.1016/j.bioorg.2018.08.018. Epub 2018 Aug 18.

PMID:
30144634
10.

Synthetic single domain antibodies for the conformational trapping of membrane proteins.

Zimmermann I, Egloff P, Hutter CA, Arnold FM, Stohler P, Bocquet N, Hug MN, Huber S, Siegrist M, Hetemann L, Gera J, Gmür S, Spies P, Gygax D, Geertsma ER, Dawson RJ, Seeger MA.

Elife. 2018 May 24;7. pii: e34317. doi: 10.7554/eLife.34317.

11.

mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma.

Holmes B, Benavides-Serrato A, Freeman RS, Landon KA, Bashir T, Nishimura RN, Gera J.

Oncogene. 2018 Feb 8;37(6):732-743. doi: 10.1038/onc.2017.360. Epub 2017 Oct 23.

12.

Structure-activity relationship study of small molecule inhibitors of the DEPTOR-mTOR interaction.

Lee J, Shi Y, Vega M, Yang Y, Gera J, Jung ME, Lichtenstein A.

Bioorg Med Chem Lett. 2017 Oct 15;27(20):4714-4724. doi: 10.1016/j.bmcl.2017.09.002. Epub 2017 Sep 6.

PMID:
28916338
13.

Noncanonical Decapentaplegic Signaling Activates Matrix Metalloproteinase 1 To Restrict Hedgehog Activity and Limit Ectopic Eye Differentiation in Drosophila.

Aggarwal P, Gera J, Ghosh S, Mandal L, Mandal S.

Genetics. 2017 Sep;207(1):197-213. doi: 10.1534/genetics.117.201053. Epub 2017 Jul 10.

14.

Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma.

Benavides-Serrato A, Lee J, Holmes B, Landon KA, Bashir T, Jung ME, Lichtenstein A, Gera J.

PLoS One. 2017 Apr 28;12(4):e0176599. doi: 10.1371/journal.pone.0176599. eCollection 2017. Erratum in: PLoS One. 2019 Feb 6;14(2):e0212160.

15.

Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.

Shi Y, Daniels-Wells TR, Frost P, Lee J, Finn RS, Bardeleben C, Penichet ML, Jung ME, Gera J, Lichtenstein A.

Cancer Res. 2016 Oct 1;76(19):5822-5831. Epub 2016 Aug 16.

16.

Impact of Anterior vs Posterior Approach for Total Hip Arthroplasty on Post-Acute Care Service Utilization.

L'Hommedieu CE, Gera JJ, Rupp G, Salin JW, Cox JS, Duwelius PJ.

J Arthroplasty. 2016 Sep;31(9 Suppl):73-7. doi: 10.1016/j.arth.2016.06.057. Epub 2016 Jul 6.

PMID:
27460301
17.

Physicians With Defined Clear Care Pathways Have Better Discharge Disposition and Lower Cost.

Tessier JE, Rupp G, Gera JT, DeHart ML, Kowalik TD, Duwelius PJ.

J Arthroplasty. 2016 Sep;31(9 Suppl):54-8. doi: 10.1016/j.arth.2016.05.001. Epub 2016 May 11.

PMID:
27329578
18.
19.

Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma.

Holmes B, Lee J, Landon KA, Benavides-Serrato A, Bashir T, Jung ME, Lichtenstein A, Gera J.

J Biol Chem. 2016 Jul 1;291(27):14146-59. doi: 10.1074/jbc.M116.726927. Epub 2016 May 11.

20.

Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness.

Artinian N, Cloninger C, Holmes B, Benavides-Serrato A, Bashir T, Gera J.

J Biol Chem. 2015 Aug 7;290(32):19387-401. doi: 10.1074/jbc.M115.656587. Epub 2015 May 21.

21.

Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress.

Shi Y, Yang Y, Hoang B, Bardeleben C, Holmes B, Gera J, Lichtenstein A.

Oncogene. 2016 Feb 25;35(8):1015-24. doi: 10.1038/onc.2015.156. Epub 2015 May 11.

22.

DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells.

Yang Y, Bardeleben C, Frost P, Hoang B, Shi Y, Finn R, Gera J, Lichtenstein A.

Genes Cancer. 2014 Nov;5(11-12):407-19.

23.

mTORC2 modulates feedback regulation of p38 MAPK activity via DUSP10/MKP5 to confer differential responses to PP242 in glioblastoma.

Benavides-Serrato A, Anderson L, Holmes B, Cloninger C, Artinian N, Bashir T, Gera J.

Genes Cancer. 2014 Nov;5(11-12):393-406.

24.

MNK1-induced eIF-4E phosphorylation in myeloma cells: a pathway mediating IL-6-induced expansion and expression of genes involved in metabolic and proteotoxic responses.

Shi Y, Frost P, Hoang B, Yang Y, Bardeleben C, Gera J, Lichtenstein A.

PLoS One. 2014 Apr 8;9(4):e94011. doi: 10.1371/journal.pone.0094011. eCollection 2014.

25.

Sick sinus syndrome: a review.

Semelka M, Gera J, Usman S.

Am Fam Physician. 2013 May 15;87(10):691-6. Review.

26.

Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis.

Frost P, Berlanger E, Mysore V, Hoang B, Shi Y, Gera J, Lichtenstein A.

J Oncol. 2013;2013:897025. doi: 10.1155/2013/897025. Epub 2013 Feb 28.

27.

Targeting cancer with a lupus autoantibody.

Hansen JE, Chan G, Liu Y, Hegan DC, Dalal S, Dray E, Kwon Y, Xu Y, Xu X, Peterson-Roth E, Geiger E, Liu Y, Gera J, Sweasy JB, Sung P, Rockwell S, Nishimura RN, Weisbart RH, Glazer PM.

Sci Transl Med. 2012 Oct 24;4(157):157ra142. doi: 10.1126/scitranslmed.3004385.

28.

Conditional astroglial Rictor overexpression induces malignant glioma in mice.

Bashir T, Cloninger C, Artinian N, Anderson L, Bernath A, Holmes B, Benavides-Serrato A, Sabha N, Nishimura RN, Guha A, Gera J.

PLoS One. 2012;7(10):e47741. doi: 10.1371/journal.pone.0047741. Epub 2012 Oct 15.

29.

A cell-penetrating bispecific antibody for therapeutic regulation of intracellular targets.

Weisbart RH, Gera JF, Chan G, Hansen JE, Li E, Cloninger C, Levine AJ, Nishimura RN.

Mol Cancer Ther. 2012 Oct;11(10):2169-73. doi: 10.1158/1535-7163.MCT-12-0476-T. Epub 2012 Aug 3.

31.

MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells.

Shi Y, Frost P, Hoang B, Yang Y, Fukunaga R, Gera J, Lichtenstein A.

Oncogene. 2013 Jan 10;32(2):190-7. doi: 10.1038/onc.2012.43. Epub 2012 Feb 27.

32.

Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, Vinters HV, Gera JF, Cavenee WK, Cloughesy TF, Manning BD, Baldwin AS, Mischel PS.

Cancer Discov. 2011 Nov;1(6):524-38. doi: 10.1158/2159-8290.CD-11-0124. Epub 2011 Sep 13.

33.

Protor-2 interacts with tristetraprolin to regulate mRNA stability during stress.

Holmes B, Artinian N, Anderson L, Martin J, Masri J, Cloninger C, Bernath A, Bashir T, Benavides-Serrato A, Gera J.

Cell Signal. 2012 Jan;24(1):309-15. doi: 10.1016/j.cellsig.2011.09.015. Epub 2011 Sep 22.

34.

Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma.

Cloninger C, Bernath A, Bashir T, Holmes B, Artinian N, Ruegg T, Anderson L, Masri J, Lichtenstein A, Gera J.

Mol Cancer Ther. 2011 Dec;10(12):2244-56. doi: 10.1158/1535-7163.MCT-11-0478. Epub 2011 Sep 12.

35.

The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.

Gera J, Lichtenstein A.

Leuk Lymphoma. 2011 Oct;52(10):1857-66. doi: 10.3109/10428194.2011.580478. Epub 2011 May 23. Review.

PMID:
21599581
36.

Phosphomimetic substitution of heterogeneous nuclear ribonucleoprotein A1 at serine 199 abolishes AKT-dependent internal ribosome entry site-transacting factor (ITAF) function via effects on strand annealing and results in mammalian target of rapamycin complex 1 (mTORC1) inhibitor sensitivity.

Martin J, Masri J, Cloninger C, Holmes B, Artinian N, Funk A, Ruegg T, Anderson L, Bashir T, Bernath A, Lichtenstein A, Gera J.

J Biol Chem. 2011 May 6;286(18):16402-13. doi: 10.1074/jbc.M110.205096. Epub 2011 Mar 16.

37.

AP-1 regulates cyclin D1 and c-MYC transcription in an AKT-dependent manner in response to mTOR inhibition: role of AIP4/Itch-mediated JUNB degradation.

Vartanian R, Masri J, Martin J, Cloninger C, Holmes B, Artinian N, Funk A, Ruegg T, Gera J.

Mol Cancer Res. 2011 Jan;9(1):115-30. doi: 10.1158/1541-7786.MCR-10-0105. Epub 2010 Dec 6.

38.

IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the rna-binding protein hnRNP A1.

Shi Y, Frost P, Hoang B, Benavides A, Gera J, Lichtenstein A.

J Biol Chem. 2011 Jan 7;286(1):67-78. doi: 10.1074/jbc.M110.153221. Epub 2010 Oct 25.

39.

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

Hoang B, Frost P, Shi Y, Belanger E, Benavides A, Pezeshkpour G, Cappia S, Guglielmelli T, Gera J, Lichtenstein A.

Blood. 2010 Nov 25;116(22):4560-8. doi: 10.1182/blood-2010-05-285726. Epub 2010 Aug 4.

41.

IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1.

Shi Y, Frost PJ, Hoang BQ, Benavides A, Sharma S, Gera JF, Lichtenstein AK.

Cancer Res. 2008 Dec 15;68(24):10215-22. doi: 10.1158/0008-5472.CAN-08-1066.

42.

Heterogeneous nuclear ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through Akt signaling.

Jo OD, Martin J, Bernath A, Masri J, Lichtenstein A, Gera J.

J Biol Chem. 2008 Aug 22;283(34):23274-87. doi: 10.1074/jbc.M801185200. Epub 2008 Jun 18. Erratum in: J Biol Chem. 2008 Nov 7;283(45):31268.

43.

Hsp70 associates with Rictor and is required for mTORC2 formation and activity.

Martin J, Masri J, Bernath A, Nishimura RN, Gera J.

Biochem Biophys Res Commun. 2008 Aug 8;372(4):578-83. doi: 10.1016/j.bbrc.2008.05.086. Epub 2008 May 27.

44.

mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor.

Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A, Gera J.

Cancer Res. 2007 Dec 15;67(24):11712-20.

45.

Protein kinase C regulates internal initiation of translation of the GATA-4 mRNA following vasopressin-induced hypertrophy of cardiac myocytes.

Sharma A, Masri J, Jo OD, Bernath A, Martin J, Funk A, Gera J.

J Biol Chem. 2007 Mar 30;282(13):9505-16. Epub 2007 Feb 6.

46.

Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling.

Marderosian M, Sharma A, Funk AP, Vartanian R, Masri J, Jo OD, Gera JF.

Oncogene. 2006 Oct 12;25(47):6277-90. Epub 2006 May 15.

PMID:
16702957
47.

Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.

Yan H, Frost P, Shi Y, Hoang B, Sharma S, Fisher M, Gera J, Lichtenstein A.

Cancer Res. 2006 Feb 15;66(4):2305-13.

49.
50.

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model.

Frost P, Moatamed F, Hoang B, Shi Y, Gera J, Yan H, Frost P, Gibbons J, Lichtenstein A.

Blood. 2004 Dec 15;104(13):4181-7. Epub 2004 Aug 10.

PMID:
15304393

Supplemental Content

Support Center